Conditions: Essential Hypertension
Keywords: Essential hypertension LCZ696
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1438
Healthy volunteers: no

Brief summary:
This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension

Detailed description:

Arms:
arm 1: Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily. arm 2: Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken. arm 3: Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.

Interventions: intervention 1: LCZ696 intervention 2: Olmesartan intervention 3: Placebo of LCZ696 intervention 4: Placebo of Olmesartan
Intervention descriptions: intervention 1: LCZ696 200 mg tablet intervention 2: Olmesartan 20 mg capsule intervention 3: Placebo tablet of LCZ696 200 mg once daily intervention 4: Placebo capsule of olmesartan 20 mg once daily

Protocol document: